Skip to content
Michigan GPRA Info
  • Home
  • SOR
  • MI-PHL (SBIRT)
  • Archive
    • MYTIE
    • PPW
  • Help

Posts

DEA and SAMHSA Buprenorphine and Telemedicine COVID-19 Guidance

March 31, 2020 Danielle Hicks

In light of the coronavirus pandemic, the Drug Enforcement Administration (DEA) has partnered with SAMHSA to ensure authorized practitioners may admit and treat new patients with opioid use disorder (OUD) during the public health emergency.


DOWNLOAD THIS DOCUMENT

dea-samhsa-buprenorphine-telemedicineDownload

dea-samhsa-buprenorphine-telemedicine

Posted in: News & Research

Post navigation

← FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency
GPRA Follow Up Timeline Infographic →

Grant Categories

  • MI-PHL (SBIRT)
    • GPRA Instruments
    • GPRA Training & Requirements
  • Michigan Youth Treatment Infrastructure Enhancement
    • Evaluation Reports
    • GPRA
    • GPRA Protocols
    • Grant Reporting
    • Infographics
  • Pregnant and Postpartum Women
    • GPRA Instruments
    • GPRA Technical Assistance
  • State Opioid Response
    • 6-Month Follow-Up Resources
    • GPRA FAQ
    • GPRA Tools
    • News & Research
    • Newsletters
    • Technical Assistance
    • Training

Archives

Have a question or concern?

Get In Touch

Additional Information

Michigan Department of Health and Human Services
Behavioral and Physical Health and Aging Services Administration
Substance Use, Gambling, and Epidemiology
(517)-335-2300
mdch-bhdda@michigan.gov

  • Home
  • About
  • Contact
Copyright © 2025 Michigan GPRA Info